Powder: -20°C for 3 years | In solvent: -80°C for 1 year
T025 is a pan CLK inhibitor with Kds of 4.8, 0.096, 6.5, 0.61, and 0.074 nM for CLK1-4, respectively. T025 displays anti-proliferative activities with IC50s of 30-300 nM in hematological and solid cancer cell lines. T025 can be used in studies about MYC-driven diseases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 146.00 | |
5 mg | In stock | $ 372.00 | |
10 mg | In stock | $ 556.00 | |
25 mg | In stock | $ 896.00 | |
50 mg | In stock | $ 1,220.00 | |
100 mg | In stock | $ 1,650.00 | |
500 mg | In stock | $ 3,290.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 397.00 |
Description | T025 is a pan CLK inhibitor with Kds of 4.8, 0.096, 6.5, 0.61, and 0.074 nM for CLK1-4, respectively. T025 displays anti-proliferative activities with IC50s of 30-300 nM in hematological and solid cancer cell lines. T025 can be used in studies about MYC-driven diseases. |
Targets&IC50 | CLK2:0.096 nM (kd), CLK4:0.61 nM (kd), CLK3:6.5 nM (kd), CLK1:4.8 nM (kd) |
In vitro | In MDA-MB-468 cells, T025 (1-1000 nM) dose-dependently suppresses cell growth and reduces pCLK2 and CLK2 phosphorylation levels[1]. |
In vivo | In Balb/c nude mice, gavage administration of T025 (50 mg/kg) suppresses tumor growth and < 10% nadir body weight loss. Gavage administration of T025 (50 mg/kg) inhibits the CLK-dependent phosphorylation and decreases the RPS6KB1 exon 7 and BCLAF1 exon 11 percentage splice-in values[1]. |
Molecular Weight | 382.42 |
Formula | C21H18N8 |
CAS No. | 2407433-00-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 7.4 mg/mL (19.4 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
T025 2407433-00-3 Cell Cycle/Checkpoint CDK T 025 T-025 inhibitor inhibit